Read this company snapshot
Daily valuation snapshot
Purple Biotech Ltd. American Depositary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $1.33
- Market capitalization (USD)
- Not reported
- Price / earnings (TTM)
- Not reported
- Price / book
- Not reported
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research PPBT in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research PPBT in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing PPBT with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $1.33 |
| Market capitalization (USD) | Not reported |
| Price / earnings (TTM) | Not reported |
| Price / book | Not reported |
No matching rows. Clear the filter to see all records.
Read PPBT's valuation metrics
Company size
Market capitalization measures the market value of the company's equity. Read it alongside revenue, earnings and debt when comparing company size.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
Price-to-book compares market equity value with recorded book equity. Intangible assets, profitability and the company's business affect how useful the comparison is.
Research Purple Biotech Ltd. American Depositary Shares with Aurora
Use the snapshot above to ask a specific question about PPBT. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow PPBT's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.